<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" xml:lang="en" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Br J Clin Pharmacol</journal-id><journal-id journal-id-type="iso-abbrev">Br J Clin Pharmacol</journal-id><journal-id journal-id-type="pmc-domain-id">279</journal-id><journal-id journal-id-type="pmc-domain">brjclinpharm</journal-id><journal-id journal-id-type="publisher-id">BCP</journal-id><journal-title-group><journal-title>British Journal of Clinical Pharmacology</journal-title></journal-title-group><issn pub-type="ppub">0306-5251</issn><issn pub-type="epub">1365-2125</issn><publisher><publisher-name>Wiley</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC7576628</article-id><article-id pub-id-type="pmcid-ver">PMC7576628.1</article-id><article-id pub-id-type="pmcaid">7576628</article-id><article-id pub-id-type="pmcaiid">7576628</article-id><article-id pub-id-type="pmid">32335930</article-id><article-id pub-id-type="doi">10.1111/bcp.14326</article-id><article-id pub-id-type="publisher-id">BCP14326</article-id><article-id pub-id-type="other">MP-00025-20.R2</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="overline"><subject>Original Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Articles</subject></subj-group></article-categories><title-group><article-title>Assessing the impact of cystic fibrosis on the antipyretic response of ibuprofen in children: Physiologically&#8208;based modeling as a candle in the dark</article-title><alt-title alt-title-type="left-running-head">Cicali et al.</alt-title></title-group><contrib-group><contrib id="bcp14326-cr-0001" contrib-type="author"><name name-style="western"><surname>Cicali</surname><given-names initials="B">Brian</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-7932-8599</contrib-id><xref ref-type="aff" rid="bcp14326-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="bcp14326-cr-0002" contrib-type="author"><name name-style="western"><surname>Long</surname><given-names initials="T">Tao</given-names></name><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-0676-391X</contrib-id><xref ref-type="aff" rid="bcp14326-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="bcp14326-cr-0003" contrib-type="author"><name name-style="western"><surname>Kim</surname><given-names initials="S">Sarah</given-names></name><xref ref-type="aff" rid="bcp14326-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="bcp14326-cr-0004" contrib-type="author" corresp="yes"><name name-style="western"><surname>Cristofoletti</surname><given-names initials="R">Rodrigo</given-names></name><xref ref-type="aff" rid="bcp14326-aff-0001">
<sup>1</sup>
</xref><address><email>rcristofoletti@cop.ufl.edu</email></address></contrib></contrib-group><aff id="bcp14326-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy</named-content>
<institution>University of Florida</institution>
<city>Orlando</city>
<named-content content-type="country-part">FL</named-content>
<country country="US">USA</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Correspondence</bold><break/>
Rodrigo Cristofoletti, Center for Pharmacometrics and Systems Pharmacology, Department of Pharmaceutics, College of Pharmacy, University of Florida, 6550 Sanger Road, Office 146, Orlando, FL 32827, USA.<break/>
Email: <email>rcristofoletti@cop.ufl.edu</email><break/></corresp></author-notes><pub-date pub-type="epub"><day>13</day><month>5</month><year>2020</year></pub-date><pub-date pub-type="ppub"><month>11</month><year>2020</year></pub-date><volume>86</volume><issue>11</issue><issue-id pub-id-type="pmc-issue-id">367307</issue-id><issue-id pub-id-type="doi">10.1111/bcp.v86.11</issue-id><fpage>2247</fpage><lpage>2255</lpage><history><date date-type="received"><day>12</day><month>1</month><year>2020</year></date><date date-type="rev-recd"><day>13</day><month>4</month><year>2020</year></date><date date-type="accepted"><day>15</day><month>4</month><year>2020</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>11</month><year>2021</year></date></event><event event-type="pmc-live"><date><day>01</day><month>11</month><year>2021</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2021-11-01 00:16:36.947"><day>01</day><month>11</month><year>2021</year></date></event></pub-history><permissions><copyright-statement content-type="article-copyright">&#169; 2020 The British Pharmacological Society</copyright-statement></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="BCP-86-2247.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf" xlink:href="file:BCP-86-2247.pdf"/><abstract><sec id="bcp14326-sec-0001"><title>Aim</title><p>The goal of this study is to present the utility of quantitative modelling for extrapolation of drug safety and efficacy to underrepresented populations in controlled clinical trials. To illustrate this, the stepwise development of an integrated disease/pharmacokinetics/pharmacodynamics model of antipyretic efficacy of ibuprofen in children with cystic fibrosis (CF) is presented along with therapy optimization suggestions.</p></sec><sec id="bcp14326-sec-0002"><title>Method</title><p>Published clinical trials, in vitro data, and drug physiochemical properties were used to develop an ibuprofen&#8208;mediated antipyresis model for febrile children also having CF. Workflow included first developing a mechanistic absorption model using in vitro&#8208;in vivo extrapolation followed by physiologically&#8208;based pharmacokinetic (PBPK) modelling. The verified PBPK model was then scaled to paediatric patients with CF. Once verified, the PBPK model was linked to an indirect response model of antipyresis for simulation of the overall antipyretic efficacy of ibuprofen in CF children.</p></sec><sec id="bcp14326-sec-0003"><title>Results</title><p>Model simulations showed therapeutic inequivalence between healthy children and paediatric patients with CF; <italic toggle="yes">C</italic>
<sub>max</sub> and AUC decreased by 39% (32&#8211;46%) and 44% (36&#8211;52%), respectively, in patients. Further, and in agreement with literature reports, predicted pharmacodynamics time courses suggest a slower onset and faster offset of action in patients compared to healthy children, 30 and 60 minutes, respectively. Exploratory simulations suggest an increase in dosing frequency for CF children as a better therapeutic strategy.</p></sec><sec id="bcp14326-sec-0004"><title>Conclusion</title><p>Model&#8208;informed approaches to leveraging knowledge obtained throughout the life cycle of drug development may play a key role in extrapolating drug efficacy and safety to underrepresented populations.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="bcp14326-kwd-0001">bioequivalence</kwd><kwd id="bcp14326-kwd-0002">paediatrics</kwd><kwd id="bcp14326-kwd-0003">PBPK</kwd><kwd id="bcp14326-kwd-0004">pharmacokinetic&#8208;pharmacodynamic</kwd><kwd id="bcp14326-kwd-0005">quality use of medicines</kwd></kwd-group><counts><fig-count count="4"/><table-count count="2"/><page-count count="9"/><word-count count="5872"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>November 2020</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.3 mode:remove_FC converted:21.10.2020</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="bcp14326-cit-9001"><string-name name-style="western"><surname>Cicali</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Long</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Kim</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Cristofoletti</surname><given-names>R</given-names></string-name>. <article-title>Assessing the impact of cystic fibrosis on the antipyretic response of ibuprofen in children: Physiologically&#8208;based modeling as a candle in the dark</article-title>. <source xml:lang="en">Br J Clin Pharmacol</source>. <year>2020</year>;<volume>86</volume>:<fpage>2247</fpage>&#8211;<lpage>2255</lpage>. <pub-id pub-id-type="doi">10.1111/bcp.14326</pub-id><pub-id pub-id-type="pmcid">PMC7576628</pub-id><pub-id pub-id-type="pmid">32335930</pub-id></mixed-citation>
</p><fn-group id="bcp14326-ntgp-0001"><fn id="bcp14326-note-0001"><p>Brian Cicali and Tao Long have contributed equally to this work and are co&#8208; first authors.</p></fn><fn id="bcp14326-note-0002"><p>The authors confirm that the PI for this paper is Dr. Rodrigo Cristofoletti.</p></fn></fn-group></notes></front></article></pmc-articleset>